Who
Michael Lee Milligan
Officer
Company insider
Files Form 4 as: Officer, Neumora Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $14K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Feb 2024
- Last trade
- 20 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,1191,436 at $3.57 | filing |
| 17 Feb 2026filed 19 Feb 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,1271,436 at $3.57 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 8 Jan 2026filed 9 Jan 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —85,391 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —38,234 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,675 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —41,250 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,391 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —38,234 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,675 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,250 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 18 Feb 2025filed 20 Feb 2025 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,3431,978 at $1.69 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —85,391 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —38,234 | filing |
News
No headline names them, or the companies they trade most, lately.